Idiopathic Membranous Nephropathy
35
3
3
10
Key Insights
Highlights
Success Rate
71% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
11.4%
4 terminated out of 35 trials
71.4%
-15.1% vs benchmark
20%
7 trials in Phase 3/4
30%
3 of 10 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 10 completed trials
Clinical Trials (35)
Rivaroxaban in Idiopathic Membranous Nephropathy
Rituximab Combined With Cyclosporine Versus Rituximab Alone in the Treatment of iMN
Different Immunosuppressive Treatment in iMN
Personalized Medicine for Membranous Nephropathy
Efficacy and Safety of LNP023 Compared With Rituximab in Subjects With Idiopathic Membranous Nephropathy
Effect of Huaier Granule on the Treatment of Idiopathic Membranous Nephropathy
the Effects of Different Treatment Schemes on Cognitive Function of Patients With Idiopathic Membranous Nephropathy
Obinutuzumab in the Management of Idiopathic Membranous Nephropathy
Study on the Application of Hyperspectral Imaging Technique in CTX Treatment of IMN
Clinical Study of QingReMoShen Granule to Treat Idiopathic Membranous Nephropathy
Study on the Application of Hyperspectral Imaging Technique in the Treatment of IMN by TAC
Efficacy of Rituximab Combined With Cyclosporine in the Treatment of Idiopathic Membranous Nephropathy
Prognostic Model of GC/CTX in the Treatment of MN
Prognostic Model of GC/TAC in the Treatment of MN
Prognostic Model of Rituximab in the Treatment of MN
Prognostic Model of TAC in the Treatment of MN
COVID-19 Infection and Idiopathic Membranous Nephropathy
The Efficacy of Prednisone and Combination Therapy With Methylprednisolone and Cyclophosphamide on IMN in Stage I.
Evaluate Rituximab Treatment for Idiopathic Membranous Nephropathy
The Effect of Danzhu Fuyuan Granule as Adjunctive Therapy for Chronic Stable Angina, Vascular Dementia and Idiopathic Membranous Nephropathy: A Bayesian Basket Trial